Abstract. Mutations or copy number gains (CNGs) of the EGFR and KRAS genes are representative alterations in lung adenocarcinomas that are individually associated with patient characteristics such as ethnicity, smoking status and gender. However, the effects of combinations of these genetic alterations have not been statistically examined. The present study analyzed previously examined lung adenocarcinoma cases in Asian (n=166) and non-Asian (n=136) individuals in whom all four EGFR and KRAS alterations had been studied. The polynomial logistic regression models were used following adjustment for gender and smoking status, and using patients without any type of EGFR/KRAS alterations as a reference. Between the two ethnic groups, EGFR CNGs (gEGFR) occurred more frequently than EGFR mutations (mEGFR) (46 vs. 38% in Asians; 21 vs. 10% in non-Asians), whereas KRAS mutations (mKRAS) were more frequent than KRAS CNGs (gKRAS) (13 vs. 7% and 35 vs. 4%, respectively). Additionally, gEGFR and gKRAS occurred significantly more frequently in respective mutant cases, and all EGFR alterations were almost exclusive of all KRAS alterations. The polynomial logistic regression models confirmed that all types of EGFR alterations were significantly more frequent among Asian individuals than among non-Asian individuals, independent of gender and smoking status (odds ratios, 2.36-6.67). KRAS alterations occurred less frequently among Asian individuals than among non-Asian individuals, although a significant difference was not detected. The present study results indicated that the EGFR and KRAS profiles, including mutations and CNGs, differ between Asian and non-Asian individuals with lung adenocarcinoma, suggesting that ethnicity strongly affects the molecular characteristics of lung adenocarcinoma.
Introduction
Activating mutations of EGFR and KRAS genes are characteristic mutations, or so-called 'driver mutations', of lung adenocarcinomas (1) (2) (3) . Approximately 80% of patients with EGFR mutations (mEGFR) respond efficiently to treatment with EGFR-tyrosine kinase inhibitors (TKIs) (1, 2) , but KRAS mutations (mKRAS) are considered to predict resistance to EGFR-TKI therapy (4) . Over the past decade, other 'driver mutations' in ALK (5), HER2 (6) , and BRAF (7) have been found in lung adenocarcinomas, although mEGFR and mKRAS remain the most frequent 'driver mutations' in lung adenocarcinomas (8) . Significantly, mEGFR and mKRAS are mutually exclusive and exhibit a characteristic association with clinical factors, particularly ethnicity; mEGFR are frequently observed in Asian individuals, women and never-smokers, but mKRAS are frequently observed in Caucasian individuals, men and smokers (9, 10) .
A copy number gain (CNG) is another mechanism of oncogenic activation (11) . A large-scale project to characterize copy number alterations in primary lung adenocarcinomas confirmed that EGFR and KRAS loci were significantly recurrent events when using a high-resolution genome-wide 2, 9 and SHINICHIRO MIYOSHI approach (12) . A recent systematic review and meta-analysis revealed that EGFR CNGs (gEGFR) were associated with responsiveness and improved survival outcomes in patients with non-small cell lung cancer (NSCLC) who were treated with EGFR-TKIs (13, 14) . Although gEGFR are reportedly frequent among never-smokers with NSCLC whose samples are collected in Western countries (15, 16) , ethnic differences in the frequency of gEGFR have not been intensively investigated. The frequency of KRAS CNGs (gKRAS) is reportedly low (7-11%) in lung adenocarcinoma (17) (18) (19) and the association between gKRAS and clinical factors has been controversial. Of particular note is the fact that gEGFR and gKRAS occur significantly frequently in mEGFR and mKRAS cases, respectively (15, (17) (18) (19) (20) . These lines of evidence suggest that a significant mutually exclusive association between EGFR and KRAS alterations is present in lung adenocarcinomas. In addition, there is already a great deal of information about ethnicity and mEGFR and mKRAS, but much less about the CNGs of these genes. Only a modest number of studies have analyzed mutations and CNGs in the same study and linked it with ethnicity. To the best of our knowledge, the concordant association between all four genetic alterations and ethnicity has not been extensively investigated using an adequate statistical method. The present study evaluated the impact of ethnic differences on the frequencies of mutations and CNGs of the EGFR and KRAS genes in lung adenocarcinomas, while considering gender and the smoking status, using a polynomial logistic regression model.
Materials and methods
Tumor samples. We have previously determined the mutational status and copy number of the EGFR and KRAS genes in resected NSCLC samples (17) . Among these samples, the present study restudied 302 surgically resected lung adenocarcinomas with complete information on mutational status and copy number of the EGFR and KRAS genes, and clinical information such as gender, smoking status and ethnicity. Genomic DNA extracted from frozen tissues was obtained from four countries: Japan [n=148; Okayama University, Okayama, Japan (n=73) and Chiba University, Chiba, Japan (n=75)], the United States (n=87), Australia (n=22) (17, 21, 22) . Briefly, genomic DNA was amplified by conventional PCR using the conditions stated in Table II . The PCR products were incubated with exonuclease I and shrimp alkaline phosphatase (GE Healthcare Life Sciences, Piscataway, NJ, USA), and sequenced using the ABI PRISM ® BigDye™ Terminator Cycle Sequencing kit (PerkinElmer, Inc., Foster City, CA, USA). All sequence variants were confirmed by sequencing the products of independent polymerase chain reaction (PCR) in each direction.
Validation of gene copy number alteration by quantitative (q)PCR assay. gEGFR and gKRAS were determined by qPCR assay using Power SYBR ® Green PCR Master Mix (Applied Biosystems Life Technologies, Foster City, CA, USA), as previously reported (17, 22) . LINE-1 was used as a reference gene for all copy number analyses. The PCR conditions of each gene are provided in Table II , and gene dosages of EGFR, KRAS and LINE-1 were calculated using the standard curve method. The relative copy number of each sample was determined to compare the ratio of the target gene and LINE-1 in each sample with the ratio in human genomic DNA (EMD Millipore, Billerica, MA, USA) as a diploid control. Based on our previous studies (17, 22) , CNG was defined as values >3.
Statistical analysis. The primary endpoint of the present cross-sectional study was to examine the ethnic differences (Asian vs. non-Asian) in EGFR and KRAS alterations (mutations and CNGs) in lung adenocarcinoma. To assess this, polynomial logistic regression models adjusted for gender (female vs. male) and smoking status (never vs. ever) were applied without any type of EGFR/KRAS alteration as a reference group. Cross-sectional odds ratios (ORs) and 95% confidence intervals (CIs) were applied as a measure of association. Each OR indicates how many times cases of Asian ethnicity are more likely to harbor the specified pattern of alteration of EGFR/KRAS than cases of non-Asian ethnicity. Fisher's exact test was used for comparing the baseline characteristics of the Asian and non-Asian groups. Exact 95% CIs were estimated with prevalence of each combination of alteration. P<0.05 was defined as a threshold of statistical significance. All the statistical analyses were executed by STATA version 11 (StataCorp LP, College Station, TX, USA).
Results

Mutations and CNGs of EGFR or KRAS and clinical
factors. mEGFR (EGFR mutation independent of EGFR CNG), gEGFR (EGFR CNG independent of EGFR mutation), mKRAS and gKRAS were present in 26% (n=77), 34% (n=104), 23% (n=69) and 6% (n=17) of the 302 cases, respectively. mEGFR, gEGFR, mKRAS and gKRAS were present in 38, 46, 13 and 7% of Asian individuals (n=166) and 10, 21, 35 and 4% of non-Asian individuals (n=136), respectively, indicating that CNGs were more frequently present than mutations in EGFR but not in KRAS between the two ethnic groups (Table I ; Fig. 1 ). mEGFR (P<0.0001), gEGFR (P<0.0001) or any EGFR alteration (mEGFR or gEGFR; P<0.0001) were significantly more frequent in Asian compared with non-Asian individuals. By contrast, mKRAS (P<0.0001) and any KRAS alteration (mKRAS or gKRAS; P=0.0001) were significantly more frequent in non-Asian compared with Asian individuals (Table I; Fig. 1 ). With regard to other clinical factors, the never smoking status was significantly associated with mEGFR (P<0.0001) and gEGFR (P=0.046), whereas the presence of a smoking history was significantly associated with mKRAS (P<0.0001; Table III ). The female gender was a significant factor that was associated with mEGFR (P=0.0005).
Inter-association between mutations and CNGs of EGFR and KRAS is retained between the two ethnic groups.
The present study evaluated the effect of ethnic difference on the inter-association between mutations and CNGs of the EGFR and KRAS genes by categorizing 302 cases into three groups according to mutational status: i) mEGFR (n=77), ii) mKRAS (n=69) and iii) wild-type for EGFR and KRAS (n=156). gEGFR (Asian individuals, P=0.338; non-Asian individuals, P=0.041) and gKRAS (Asian individuals, P=0.007; non-Asian individuals, P= 0.124) occurred significantly more frequently in their respective mutant cases (Fig. 2) . Between the Asian and non-Asian individuals, the frequencies of gEGFR and gKRAS were lowest in the mKRAS and mEGFR groups, respectively (Fig. 2) . mEGFR and mKRAS were completely mutually exclusive in the two ethnic groups and any EGFR alterations (either mEGFR or gEGFR) were almost exclusive with any KRAS alterations (either mKRAS or gKRAS) between the two ethnic groups (P= 0.016 in Asians and P= 0.004 in non-Asians). These findings suggested that the inter-association between the mutation and CNG of an identical gene and between alterations of the EGFR and KRAS genes were retained in the two ethnic groups. 
Ethnic differences of EGFR and KRAS alterations with respect to gender and smoking status.
As gender and smoking status were other significant factors associated with the frequency of the mutations and CNGs of the EGFR and KRAS genes (Table III) and as the proportions of females and never-smokers were significantly biased toward the Asian group, a polynomial logistic regression model was performed with adjustments for gender and smoking status; patients without any EGFR/KRAS alterations were used as the reference group (Table IV) . According to the polynomial logistic regression models, it Table III . Association between EGFR and KRAS alterations and characteristics in 302 lung adenocarcinomas.
mEGFR (n=77) gEGFR (n=104) mKRAS (n=69) gKRAS (n=17) -----------------------------------------------------------------------------------------------------------------------------------------------------------------Subsets
Total, n n % P-value n % P-value n % P-value n % P-value was confirmed that all types of EGFR alterations [mEGFR (P<0.001), gEGFR (P=0.005), mgEGFR (mutation and CNG of EGFR gene; P<0.001), any EGFR (P<0.001), mEGFR alone (mEGFR without EGFR CNG; P<0.001) and gEGFR alone (gEGFR without EGFR mutation; P= 0.017)] were significantly more frequent among Asian individuals compared with among non-Asian individuals (ORs, 2.36-6.67). KRAS alterations occurred less frequently among Asian individuals than among non-Asian individuals, although a statistical significance was not detected using the polynomial model. Additionally, the 302 cases were subcategorized into 8 groups according to gender, smoking status and ethnicity: i) Asian never-smoker, female (A-NS-F; n=58), ii) Asian never-smoker, male (A-NS-M; n=17), iii) Asian smoker, female (A-SM-F; n=12), iv) Asian smoker, male (A-SM-M; n=79), v) non-Asian never-smoker, female (NA-NS-F; n=26), vi) non-Asian never-smoker, female (NA-NS-M; n=14), vii) non-Asian smoker, female (NA-SM-F; n=47), and viii) non-Asian smoker, male (NA-SM-M; n=49). Each group was compared, noting the effect of ethnicity on the frequencies of these genetic alterations (Fig. 3) . mEGFR and gEGFR occurred more frequently in every Asian group than in their corresponding non-Asian group, independent of gender and smoking status, whereas mKRAS occurred more frequently in non-Asians than in Asians among the smoker groups, but this ethnic difference was not observed among the never-smoker groups (Fig. 3) .
Discussion
The present study investigated the impact of ethnic differences on the genetic alterations of EGFR and/or KRAS genes, and found that ethnic differences were associated with the frequencies of these genetic alterations, particularly EGFR alterations, even when gender and smoking status were taken into consideration. Ethnic differences in the frequencies of molecular alterations have been described in several studies. We previously reported that the frequencies of the aberrant methylation of CpG islands in certain tumor-suppressor genes, such as MGMT and GSTP1, were different between non-Asian populations (American and Australian cases) and Asian populations (Japanese and Taiwanese cases) (23) . A recent study that evaluated CNGs in lung adenocarcinomas using a common high-resolution single nucleotide polymorphism microarray, also reported that discrete differences in copy number aberrations was present between East-Asian and Western European individuals (chromosome 16p CNGs in East-Asian individuals, and chromosome 19p losses in Western European individuals) (24) . Oncogenes can be activated by mutations, CNGs and/or translocations (11) . Any one of these genetic alterations is able to activate oncogenes, but interactions among these alterations can occur. In fact, the EGFR and KRAS genes are known to be activated by activating mutations and CNGs, and the inter-association between these genetic alterations have been investigated in previous studies (15, 17, 18, 25) . Although these studies have not revealed ethnic differences for these genetic alterations, it has been reported that i) the EGFR gene is more dominantly activated by CNGs than by mutations, while the KRAS gene is more activated by mutations than by CNGs; ii) mEGFR and mKRAS are mutually exclusive; and iii) gEGFR and gKRAS occur significantly more frequently among their respective mutant cases. As a result of these findings, EGFR alterations (mEGFR and/or gEGFR) may be almost exclusive of KRAS alterations, as confirmed in the present study. This study added novel insights into the inter-association between these genetic alterations and ethnicity. The inter-association between mutations and CNGs of the same gene, and between alterations of the EGFR and KRAS genes, were similar in the Asian and non-Asian groups: i.e., in each ethnic group, gEGFR and gKRAS were significantly frequent among the respective mutant cases, and EGFR alterations (mEGFR and/or gEGFR) were exclusive of KRAS alterations. This fact strongly suggests that the inter-association between CNG and mutations in each gene is retained in Asian and non-Asian ethnicities.
In the present study, DNA samples were collected from four countries with mixed populations of different ethnicities, such as Japanese, other Asian (non-Japanese), Caucasian, African-American and Mexican-American. A total of 4 African-Americans were included in the non-Asian group, as African-Americans have been reported to show similar frequencies of mEGFR and mKRAS to Caucasians (26) (27) (28) , and it was confirmed that none of the 4 African-Americans harbored mEGFR and that 2 harbored mKRAS. The mutations and CNGs in 12 Asian patients with lung adenocarcinomas whose DNA samples were obtained from Western countries were also determined. It was confirmed that EGFR alterations were more frequent than KRAS alterations among these Asians samples (data not shown), as previously reported (29) . In addition, Asian patients with NSCLC who immigrated to Canada from Asian countries reportedly showed a preferential response to EGFR-TKI treatment (30) . These lines of evidence suggest that ethnic differences in the molecular spectra of EGFR and KRAS are not affected by environmental factors, and that ethnicity is an important factor determining the molecular spectrum of lung adenocarcinoma.
In conclusion, the EGFR and KRAS profiles in lung adenocarcinoma differ between Asian and non-Asian populations, suggesting that ethnicity affects the molecular characteristics of lung adenocarcinoma.
